[Source: Earth Times] – ImmuneRegen BioSciences®, a wholly owned subsidiary of IR Biosciences Holdings Inc. (OTCBB: IRBS), today announced that, in collaboration with Dr. Jacob Finkelstein at the University of Rochester School of Medicine, they have submitted a proposal to the U.S. government seeking funding to develop Homspera® as a post-exposure therapy for injury resulting from ionizing radiation exposure.
The proposal [a Broad Agency Announcement (BAA), sponsored by The Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services] expands on research ImmuneRegen has previously performed demonstrating efficacy of Homspera in treating pulmonary injury as well as mitigating acute effects, including the hematopoietic syndrome, resulting from exposure to ionizing radiation. The proposal utilizes animal models validated at the University of Rochester using NIAID funding that accurately depict the short- and long-term pulmonary symptomatology (pneumonitis and fibrosis respectively) that follow exposure to ionizing radiation. ImmuneRegen recently filed an Investigational New Drug (IND) application with the FDA for a similar indication, idiopathic pulmonary fibrosis.
For more information: ImmuneRegen BioSciences(R) Partners With University of Rochester in BARDA Funding Bid